Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes-Reference-Cited by-同舟云学术

Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes

Published:2015-08 Issue:3 Volume:116 Page:339-343
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Bonello Laurent,Laine Marc,Cluzel Marion,Frere Corinne,Mancini Julien,Hasan Aurasse,Thuny Franck,Gaubert Mélanie,Guieu Régis,Dignat-George Françoise,Michelet Pierre,Paganelli Franck,Kerbaul François

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference21 articles.

1. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

2. 2014 ESC/EACTS Guidelines on myocardial revascularization

3. Pre-treatment with prasugrel in non-ST-segment elevation acute coronary syndromes;Montalescot;N Engl J Med,2013

4. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study;Parodi;J Am Coll Cardiol,2013

5. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention;Mangiacapra;JACC Cardiovasc Interv,2010

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of preloading strategy with ticagrelor on periprocedural myocardial injury in patients with non-ST elevation myocardial infarction undergoing early invasive strategy;Journal of Cardiovascular Pharmacology;2024-01-15

2. Potent P2Y12 Inhibitor Selection and De-Escalation Strategies in Acute Coronary Syndrome Patients Undergoing PCI: Systematic Review and Meta-analysis;CJC Open;2023-12

3. Effect of pretreatment with a P2Y12 inhibitor in patients with non-ST-elevation acute coronary syndrome: a systematic review and network meta-analysis;Frontiers in Cardiovascular Medicine;2023-07-19

4. Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Expert Opinion on Pharmacotherapy;2023-02-07

5. Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI;JACC: Cardiovascular Interventions;2023-01